BidaskClub downgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a strong sell rating in a research report report published on Saturday.

ACHN has been the subject of a number of other reports. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a hold rating to a buy rating and set a $4.50 price target for the company in a research note on Monday, November 6th. Chardan Capital reaffirmed a neutral rating on shares of Achillion Pharmaceuticals in a research note on Sunday, September 17th. Finally, Leerink Swann reaffirmed a buy rating and issued a $5.00 price target on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $5.13.

Achillion Pharmaceuticals (NASDAQ ACHN) remained flat at $$2.99 during trading on Friday. 1,467,546 shares of the stock were exchanged, compared to its average volume of 2,774,815. The stock has a market capitalization of $412.20, a price-to-earnings ratio of -6.23 and a beta of 1.53. Achillion Pharmaceuticals has a 1 year low of $2.69 and a 1 year high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. During the same quarter last year, the business earned ($0.15) earnings per share. equities analysts predict that Achillion Pharmaceuticals will post -0.63 earnings per share for the current fiscal year.

In other news, major shareholder & Johnson Johnson sold 18,367,346 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.24% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACHN. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Achillion Pharmaceuticals by 3.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 800 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Achillion Pharmaceuticals by 18.6% in the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 4,144 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Achillion Pharmaceuticals by 53.8% in the 2nd quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 15,000 shares in the last quarter. Voya Investment Management LLC raised its holdings in shares of Achillion Pharmaceuticals by 13.7% in the 2nd quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 6,730 shares in the last quarter. Finally, CIBC World Markets Inc. bought a new stake in shares of Achillion Pharmaceuticals in the 2nd quarter worth approximately $280,000. Institutional investors and hedge funds own 76.92% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/14/achillion-pharmaceuticals-achn-rating-lowered-to-strong-sell-at-bidaskclub.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.